MD20120127A2 - Recombinant Koi herpesvirus (KHV), method for its production and vaccine for the prevention of a disease caused by KHV - Google Patents

Recombinant Koi herpesvirus (KHV), method for its production and vaccine for the prevention of a disease caused by KHV

Info

Publication number
MD20120127A2
MD20120127A2 MDA20120127A MD20120127A MD20120127A2 MD 20120127 A2 MD20120127 A2 MD 20120127A2 MD A20120127 A MDA20120127 A MD A20120127A MD 20120127 A MD20120127 A MD 20120127A MD 20120127 A2 MD20120127 A2 MD 20120127A2
Authority
MD
Moldova
Prior art keywords
khv
prevention
production
vaccine
koi herpesvirus
Prior art date
Application number
MDA20120127A
Other languages
English (en)
Romanian (ro)
Other versions
MD4481B1 (ro
MD4481C1 (ro
Inventor
Alain Francis Claude Vanderplasschen
Original Assignee
Univ Liege
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Liege filed Critical Univ Liege
Publication of MD20120127A2 publication Critical patent/MD20120127A2/mo
Publication of MD4481B1 publication Critical patent/MD4481B1/ro
Publication of MD4481C1 publication Critical patent/MD4481C1/ro

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • A61K39/245Herpetoviridae, e.g. herpes simplex virus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • A61P31/22Antivirals for DNA viruses for herpes viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525Virus
    • A61K2039/5254Virus avirulent or attenuated
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525Virus
    • A61K2039/5256Virus expressing foreign proteins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/55Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552Veterinary vaccine
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/16011Herpesviridae
    • C12N2710/16021Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/16011Herpesviridae
    • C12N2710/16022New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/16011Herpesviridae
    • C12N2710/16034Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/16011Herpesviridae
    • C12N2710/16041Use of virus, viral particle or viral elements as a vector
    • C12N2710/16043Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/16011Herpesviridae
    • C12N2710/16051Methods of production or purification of viral material
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/16011Herpesviridae
    • C12N2710/16061Methods of inactivation or attenuation
    • C12N2710/16062Methods of inactivation or attenuation by genetic engineering
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00Nucleic acids vectors
    • C12N2800/20Pseudochromosomes, minichrosomosomes
    • C12N2800/204Pseudochromosomes, minichrosomosomes of bacterial origin, e.g. BAC

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Farming Of Fish And Shellfish (AREA)
MDA20120127A 2011-12-30 2012-12-27 Herpesvirus recombinant Koi (KHV) şi vaccin pentru profilaxia bolii cauzate de KHV MD4481C1 (ro)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP11196171 2011-12-30

Publications (3)

Publication Number Publication Date
MD20120127A2 true MD20120127A2 (en) 2013-07-31
MD4481B1 MD4481B1 (ro) 2017-05-31
MD4481C1 MD4481C1 (ro) 2017-12-31

Family

ID=47429841

Family Applications (1)

Application Number Title Priority Date Filing Date
MDA20120127A MD4481C1 (ro) 2011-12-30 2012-12-27 Herpesvirus recombinant Koi (KHV) şi vaccin pentru profilaxia bolii cauzate de KHV

Country Status (18)

Country Link
US (2) US20140348875A1 (mo)
EP (1) EP2797627B1 (mo)
JP (3) JP5982009B2 (mo)
CN (1) CN104159609B (mo)
BR (1) BR112014016117A2 (mo)
HU (1) HUE053075T2 (mo)
IL (1) IL232902A0 (mo)
IN (1) IN2014CN04655A (mo)
MD (1) MD4481C1 (mo)
MX (1) MX361408B (mo)
PH (1) PH12014501388A1 (mo)
PL (1) PL2797627T3 (mo)
RS (1) RS61261B1 (mo)
RU (1) RU2662768C2 (mo)
SG (1) SG11201403066TA (mo)
TW (1) TWI484034B (mo)
UA (2) UA114719C2 (mo)
WO (1) WO2013098214A1 (mo)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2662768C2 (ru) * 2011-12-30 2018-07-31 Гесвал с.а. Рекомбинантный герпесвирус кои (khv) и вакцина для профилактики заболевания, вызываемого khv
WO2017177071A1 (en) * 2016-04-08 2017-10-12 William Marsh Rice University Improved galactose utilization
RU2736472C2 (ru) * 2016-11-18 2020-11-17 Общество с ограниченной ответственностью "ЭКСИФАРМ" Химерный белок, синтетическая днк, кодирующая указанный белок, экспрессионный вектор, штамм-продуцент синтетической днк и способ получения плазмидной днк
CN112279897B (zh) * 2018-11-05 2021-12-28 深圳技术大学 一种预防或治疗鱼类感染CyHV-2的试剂及应用
EP3662929A1 (en) * 2018-12-07 2020-06-10 IDT Biologika GmbH A recombinant koi herpesvirus (khv) and a diva vaccine for preventing and/or treating a disease caused by khv
CN110101854B (zh) * 2019-05-14 2022-08-02 四川农业大学 一种鲤疱疹病毒ⅲ型疫苗及其制备方法
CN110468111B (zh) * 2019-08-07 2022-06-17 西北农林科技大学 一种展示CyHV-2膜蛋白的重组杆状病毒及其制备方法和应用
CN110452926B (zh) * 2019-08-07 2022-06-17 西北农林科技大学 一种展示CyHV-2膜蛋白的重组杆状病毒及其制备方法和应用
CN113679832A (zh) * 2021-05-24 2021-11-23 苏州大学 一种利用冷冻干燥制备杆状病毒载鲤疱疹病毒ii型dna疫苗的方法
CN115960903B (zh) * 2022-12-23 2023-09-08 中国水产科学研究院淡水渔业研究中心 一种抑制CyHV-2病毒增殖的反义RNA组、重组载体和纳米粒递送系统及应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2068989T3 (es) 1989-02-04 1995-05-01 Akzo Nobel Nv Tocoles como adyuvante en vacunas.
DE19733364A1 (de) 1997-08-01 1999-02-04 Koszinowski Ulrich H Prof Verfahren zur Klonierung eines großen Virusgenoms
IL153775A0 (en) * 2003-01-01 2003-07-31 Yissum Res Dev Co Immunizing fish against viral infection
JP2007223913A (ja) * 2006-02-21 2007-09-06 Kyoritsu Seiyaku Kk コイヘルペスウイルス病ワクチン
JP5239023B2 (ja) * 2006-04-13 2013-07-17 国立大学法人東京海洋大学 コイヘルペスウイルス(khv)病用dnaワクチン
MD20100029A2 (ro) * 2007-08-28 2010-08-31 Льежский Университет Herpesvirus recombinant al crapului de koi (KHV) sau Cyprinid herpesvirus 3 (CyHV-3) şi vaccin pentru prevenirea bolii cauzate de KHV/CyHV-3 la Cyprinus carpio carpio sau Cyprinus carpio koi
DE102007041332A1 (de) * 2007-08-31 2009-03-05 Siemens Ag Transferchuck zur Übertragung, insbesondere von Wafern
RU2662768C2 (ru) * 2011-12-30 2018-07-31 Гесвал с.а. Рекомбинантный герпесвирус кои (khv) и вакцина для профилактики заболевания, вызываемого khv

Also Published As

Publication number Publication date
RS61261B1 (sr) 2021-01-29
MD4481B1 (ro) 2017-05-31
MX361408B (es) 2018-12-04
JP5982009B2 (ja) 2016-08-31
CN104159609B (zh) 2018-05-22
TWI484034B (zh) 2015-05-11
RU2662768C2 (ru) 2018-07-31
EP2797627A1 (en) 2014-11-05
CN104159609A (zh) 2014-11-19
EP2797627B1 (en) 2020-10-07
PH12014501388A1 (en) 2014-09-22
JP2016195593A (ja) 2016-11-24
US20140348875A1 (en) 2014-11-27
JP2018078903A (ja) 2018-05-24
IN2014CN04655A (mo) 2015-09-18
IL232902A0 (en) 2014-07-31
TW201333201A (zh) 2013-08-16
JP2015503914A (ja) 2015-02-05
BR112014016117A2 (pt) 2018-09-25
US9931396B2 (en) 2018-04-03
HUE053075T2 (hu) 2021-06-28
UA114719C2 (uk) 2017-07-25
MD4481C1 (ro) 2017-12-31
PL2797627T3 (pl) 2021-06-28
UA119786C2 (uk) 2019-08-12
WO2013098214A1 (en) 2013-07-04
US20170028057A1 (en) 2017-02-02
RU2014131474A (ru) 2016-02-20
MX2014008045A (es) 2014-10-24
SG11201403066TA (en) 2014-10-30

Similar Documents

Publication Publication Date Title
PH12014501388A1 (en) A recombinant koi herpesvirus (khv) and vaccine for the prevention of a disease caused by khv
NZ630649A (en) Vaccine against rsv
NZ708144A (en) Recombinant adenoviruses and use thereof
MX343048B (es) Oligodesoxinucleotidos inmunoestimulantes.
MX2013013800A (es) Oligodesoxinucleotidos inmunoestimuladores.
MX2013013801A (es) Oligodesoxinucleotidos inmunoestimuladores.
IN2014DN05670A (mo)
MX2014009909A (es) Acido nucleico que comprende o codifica un tallo-bucle de histona y una secuencia poli(a) o una señal de poliadenilacion para incrementar la expresion de un antigeno tumoral codificado.
WO2013106834A3 (en) Immunogenic wt-1 peptides and methods of use thereof
MX359954B (es) Ácido nucleico que comprende o codifica para un asa troncal de histona y una secuencia poly (a) o una señal de poliadenilación para aumentar la expresión de un antígeno patogénico codificado.
NZ703597A (en) Mutant fragments of ospa and methods and uses relating thereto
MX2014004814A (es) Compuestos y metodos para mejorar las respuestas inmunes innatas.
PL2771329T3 (pl) Nowe związki di-podstawione 3,4-diamino-3-cyklobuteno- 1,2-dionu do zastosowania w leczeniu patologii, w których pośredniczą chemokiny
WO2013006569A3 (en) Herpes virus vaccine and methods of use
IN2014DN06920A (mo)
MX347911B (es) Vacuna contra virus de diarrea viral de bovinos.
DK201370530A (en) Salmonid alphavirus vaccine
EP2870251A4 (en) Recombinant low virulence bovine herpesvirus 1 (bohv-1) vaccine vectors
EA201591095A1 (ru) Белок slurp-1 для применения в лечении глазных болезней
MX360449B (es) Vacunas para el virus del papiloma humano y metodos para su uso.
WO2012149525A3 (en) Ureaplasma vaccine and antibody for prevention and treatment of human, animal and cell culture infection
EP2879705A4 (en) PEPTIDE VACCINES BASED ON THE EGFRVIII SEQUENCE FOR THE TREATMENT OF TUMORS
WO2013093629A3 (en) Modular vaccines, methods and compositions related thereto
WO2012158639A3 (en) Recombinant fusion proteins and methods for use thereof for treatment or prevention of papillomavirus infection
TH158445A (th) รีคอมบิแนนท์คอยเฮอร์ปีส์ไวรัส (khv) และวัคซีนสำหรับการป้องกันของโรคที่ได้รับการทำให้เกิดขึ้นโดย khv

Legal Events

Date Code Title Description
GB9A Change of applicant (patent for invention)

Owner name: GESVAL S.A., BE AVENUE PRE-AILY, 4, B-4031 ANGLEUR

Free format text: PREVIOUS APPLICANT: UNIVERSITE DE LIEGE, BE AVENUE PRE-AILY, 4, B-4031 ANGLEUR, BELGIA

FG4A Patent for invention issued
KA4A Patent for invention lapsed due to non-payment of fees (with right of restoration)
MM4A Patent for invention definitely lapsed due to non-payment of fees